SCHEMBL5652485

SCHEMBL5652485

CC(C)(C)OC(=O)NC(c1ccc([N+](=O)[O-])cc1)C1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 3/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39
SMYD3 Q9H7B4 5/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
CYP2D6 P10635 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
GAA P10253 1/20 0.37
ALOX5 P09917 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16394313 0.84 AAK1 (0.45) ALDH1A1MAPTSMYD3AAK1NPC1
SCHEMBL5653707 0.84 SMYD3 (0.44) SLC6A3ALDH1A1MAPTSMYD3MAPK1
SCHEMBL4116055 0.83 SMYD3 (0.53) ALDH1A1SMYD3MAPK1KMT2A
SCHEMBL948775 0.82 PDE2A (0.47) PPARGPPARASMYD3AAK1SLC6A2
SCHEMBL382374 0.80 HPGD (0.44) SLC6A3LMNASMYD3KMT2ACYP2D6
SCHEMBL4715527 0.77 SMYD3 (0.46) SLC6A3SMYD3CYP2D6SLC6A2SLC6A4
SCHEMBL4715530 0.77 SMYD3 (0.46) SLC6A3SMYD3CYP2D6SLC6A2SLC6A4
SCHEMBL1628549 0.76 ALDH1A1 (0.50) PPARGPPARAALDH1A1MAPTLMNA
SCHEMBL1231134 0.76 ALDH1A1 (0.50) PPARGPPARAALDH1A1MAPTLMNA
SCHEMBL1231133 0.76 ALDH1A1 (0.50) PPARGPPARAALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ SLC6A3 2673/4885PPARG 2558/4885PPARA 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.